Cardiotoxicity of immune checkpoint inhibitors: A meta-analysis of randomized clinical trials

被引：0
|
作者：
Agostinetto, E. [1 ]
Eiger, D. [1 ]
Lambertini, M. [2 ]
Ceppi, M. [3 ]
Bruzzone, M. [3 ]
Ponde, N. F. [4 ]
Plummer, C. [5 ]
Awada, A. H. [6 ]
Piccart, M. [6 ]
de Azambuja, E. [1 ]
机构：
[1] Inst Jules Bordet, Acad Trials Promoting Team, Brussels, Belgium
[2] IRCCS Osped Policlin San Martino, Dept Med Oncol, Genoa, Italy
[3] IRCCS Osped Policlin San Martino, Unit Clin Epidemiol, Genoa, Italy
[4] AC Camargo Canc Ctr, Clin Oncol, Sao Paulo, Brazil
[5] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England
[6] Inst Jules Bordet, Oncol Dept, Brussels, Belgium
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.528
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
41P
引用
收藏
页码：S1432 / S1432
页数：1
相关论文
共 50 条
  • [31] CAPECITABINE RELATED CARDIOTOXICITY: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Alkharji, Samah
    Thao Huynh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1538 - 1538
  • [32] Cardiotoxicity of Immune Checkpoint Inhibitors
    Patel, Rushin P.
    Parikh, Rohan
    Gunturu, Krishna S.
    Tariq, Rana Zouveenoor
    Dani, Sourbha S.
    Ganatra, Sarju
    Nohria, Anju
    CURRENT ONCOLOGY REPORTS, 2021, 23 (07)
  • [33] Cardiotoxicity of immune checkpoint inhibitors
    Varricchi, Gilda
    Galdiero, Maria Rosaria
    Marone, Giancarlo
    Criscuolo, Gjada
    Triassi, Maria
    Bonaduce, Domenico
    Marone, Gianni
    Tocchetti, Carlo Gabriele
    ESMO OPEN, 2017, 2 (04)
  • [34] Cardiotoxicity of Immune Checkpoint Inhibitors
    Rushin P. Patel
    Rohan Parikh
    Krishna S. Gunturu
    Rana Zouveenoor Tariq
    Sourbha S. Dani
    Sarju Ganatra
    Anju Nohria
    Current Oncology Reports, 2021, 23
  • [35] Cardiotoxicity of Immune Checkpoint Inhibitors
    Zhang L.
    Jones-O’Connor M.
    Awadalla M.
    Zlotoff D.A.
    Thavendiranathan P.
    Groarke J.D.
    Villani A.-C.
    Lyon A.R.
    Neilan T.G.
    Current Treatment Options in Cardiovascular Medicine, 2019, 21 (7)
  • [36] Cardiotoxicity with immune checkpoint inhibitors
    Rajamani, Sridharan
    Zafra, Christina D.
    Turk, Jim
    Lebrec, Herve
    Vargas, Hugo M.
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2021, 111
  • [37] Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials
    Iacovelli, R.
    Ciccarese, C.
    Schutz, F. A.
    Tortora, G.
    de Velasco, G.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (10) : 798.e17 - 798.e24
  • [38] Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
    Grassadonia, Antonino
    Sperduti, Isabella
    Vici, Patrizia
    Iezzi, Laura
    Brocco, Davide
    Gamucci, Teresa
    Pizzuti, Laura
    Maugeri-Sacca, Marcello
    Marchetti, Paolo
    Cognetti, Gaetana
    De Tursi, Michele
    Natoli, Clara
    Barba, Maddalena
    Tinari, Nicola
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (12)
  • [39] Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials
    Dang, Shoutao
    Zhang, Shurong
    Zhao, Jingyang
    Li, Xinyu
    Li, Wei
    CANCER MEDICINE, 2023, 12 (20): : 20277 - 20286
  • [40] Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer
    Berti, Alvise
    Bortolotti, Roberto
    Dipasquale, Mariachiara
    Kinspergher, Stefania
    Prokop, Larry
    Grandi, Guido
    Inchiostro, Sandro
    Paolazzi, Giuseppe
    Caffo, Orazio
    Veccia, Antonello
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 162
12345